X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse VENUS REMEDIES with MYLAN INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs MYLAN (US) - Comparison Results

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 VENUS REMEDIES   MYLAN
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-17
MYLAN
Dec-14
VENUS REMEDIES/
MYLAN
5-Yr Chart
Click to enlarge
High Rs1434,183-   
Low Rs652,948-   
Sales per share (Unadj.) Rs324.21,431.9-  
Earnings per share (Unadj.) Rs6.4172.5-  
Cash flow per share (Unadj.) Rs40.6277.7-  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs366.0711.8-  
Shares outstanding (eoy) m12.34378.37-   
Bonus/Rights/Conversions -OI-  
Price / Sales ratio x0.32.5 12.9%   
Avg P/E ratio x16.220.7 78.4%  
P/CF ratio (eoy) x2.612.8 19.9%  
Price / Book Value ratio x0.35.0 5.7%  
Dividend payout %00-   
Avg Mkt Cap Rs m1,2821,348,943 0.1%   
No. of employees `0000.925.0 3.6%   
Total wages/salary Rs m2510-   
Avg. sales/employee Rs Th4,430.121,671.6 20.4%   
Avg. wages/employee Rs Th278.00-   
Avg. net profit/employee Rs Th87.62,610.7 3.4%   
INCOME DATA
Net Sales Rs m4,000541,790 0.7%  
Other income Rs m23-3,158 -0.7%   
Total revenues Rs m4,023538,632 0.7%   
Gross profit Rs m785134,746 0.6%  
Depreciation Rs m42239,792 1.1%   
Interest Rs m34423,370 1.5%   
Profit before tax Rs m4268,426 0.1%   
Minority Interest Rs m0-281 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-372,877 -1.3%   
Profit after tax Rs m7965,267 0.1%  
Gross profit margin %19.624.9 78.9%  
Effective tax rate %-87.94.2 -2,090.0%   
Net profit margin %2.012.0 16.4%  
BALANCE SHEET DATA
Current assets Rs m2,606476,305 0.5%   
Current liabilities Rs m1,980372,375 0.5%   
Net working cap to sales %15.619.2 81.6%  
Current ratio x1.31.3 102.9%  
Inventory Days Days12878 164.3%  
Debtors Days Days43107 40.2%  
Net fixed assets Rs m5,353125,341 4.3%   
Share capital Rs m12319,159 0.6%   
"Free" reserves Rs m4,3930-   
Net worth Rs m4,516269,323 1.7%   
Long term debt Rs m1,618402,342 0.4%   
Total assets Rs m8,2911,084,807 0.8%  
Interest coverage x1.13.9 28.6%   
Debt to equity ratio x0.41.5 24.0%  
Sales to assets ratio x0.50.5 96.6%   
Return on assets %5.18.2 62.4%  
Return on equity %1.824.2 7.2%  
Return on capital %6.313.6 46.2%  
Exports to sales %00-   
Imports to sales %18.40-   
Net fx Rs m-7360-   
CASH FLOW
From Operations Rs m99771,219 1.4%  
From Investments Rs m-461-56,165 0.8%  
From Financial Activity Rs m-571-18,766 3.0%  
Net Cashflow Rs m-35-3,713 0.9%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 70.18 Rs / USD

Compare VENUS REMEDIES With: ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare VENUS REMEDIES With: PFIZER  J.B.CHEMICALS  MERCK LTD  NATCO PHARMA  STERLING BIOTECH  



Today's Market

Sensex Ends 284 Points Up; FMCG & Metal Stocks Top Gainers(Closing)

Indian share markets settled higher today taking cues from their Asian peers. At the closing bell, BSE Sensex ended up by 284 points.

Related Views On News

VENUS REMEDIES Announces Quarterly Results (4QFY18); Net Profit Down 307.2% (Quarterly Result Update)

Jun 12, 2018 | Updated on Jun 12, 2018

For the quarter ended March 2018, VENUS REMEDIES has posted a net profit of Rs 94 m (down 307.2% YoY). Sales on the other hand came in at Rs 932 m (up 16.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

Eris Lifesciences Limited (IPO)

Jun 15, 2017

Exposure to high margin specialty products offers promising growth prospects.

More Views on News

Most Popular

This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)

Aug 8, 2018

Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why

Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)

Aug 9, 2018

Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...

Only on WhatsApp, a Weaker Rupee Means a Weaker India(Vivek Kaul's Diary)

Aug 16, 2018

While dollar crossing Rs 70 will have its repercussions, the world isn't exactly coming to an end.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Aug 17, 2018 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES - WYETH LTD COMPARISON

COMPARE VENUS REMEDIES WITH

MARKET STATS